Front Page News
Cure SMA Supports Clinical Trial Readiness
In recent years, the FDA-approval of three new SMA treatments has made it possible for a growing number of affected individuals to receive disease-modifying drugs. […]
Read More ›Cure SMA Awards $150,000 Grant to Alberto Kornblihtt, PhD, Universidad de Buenos Aires
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA […]
Read More ›Cure SMA Unveils Advocacy 101 Video Series in Conjunction with 118th Congress
Individuals with SMA and their families can learn how to advocate with their Members of Congress more effectively on issues important to them and the […]
Read More ›Genentech Releases SMA Community Letter
Our industry partners at Genentech recently released an SMA community letter summarizing 2022 developments and initiates. Check it out here!
Read More ›Share Your Air Travel Concerns & Experiences for Cure SMA Report to Congress
The law that governs air travel in the United States is about to expire. Next year, Congress must consider air travel changes through a new […]
Read More ›SMA Community Progress & Advocacy Featured at Cure SMA Hope on the Hill Event
Congressional leaders and key partners, supporters, and members of the spinal muscular atrophy (SMA) community celebrated SMA achievements and advocacy at Cure SMA’s 11th Annual […]
Read More ›Cure SMA to Host 11th Annual Hope on the Hill Event in Washington, D.C.
On December 6th, Cure SMA will highlight the progress made in spinal muscular atrophy (SMA) and recognize the advocacy that helped lead to this success […]
Read More ›Biogen Releases Q3 SMA Community Statement
Learn about Biogen’s latest news in SMA by viewing their Community Statement and a related video.
Read More ›The Giving Season is Here!
Cure SMA leads the way to a world where everyone impacted by SMA is empowered to lead their best lives. As 2022 comes to a […]
Read More ›Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
Genentech, announced earlier this month new two-year data from the JEWELFISH study evaluating Evrysdi® (risdiplam) in people with Type 1, 2 or 3 SMA aged 6 […]
Read More ›